FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Blunt Roshawn A.
2. Issuer Name and Ticker or Trading Symbol

Adamis Pharmaceuticals Corp [ ADMP ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

11682 EL CAMINO REAL STE 300
3. Date of Earliest Transaction (MM/DD/YYYY)

8/26/2019
(Street)

SAN DIEGO, CA 92130
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Appreciation Right $.97 (1)8/26/2019  A   50000     (2)8/26/2026 Common Stock 50000 $0 50000 D  

Explanation of Responses:
(1) Each Stock Appreciation Right is the economic equivalent of one share of ADMP common stock and can only be settled in cash.
(2) The Stock Appreciation Right ("SAR") will vest with respect to 8,333 shares subject to the SAR on the six-month anniversary of the date of grant, and thereafter 1,388 shares shall vest on each monthly anniversary of the date of grant with all remaining unvested shares subject to the SAR vesting on the thirty-sixth (36th) monthly anniversary of the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Blunt Roshawn A.
11682 EL CAMINO REAL STE 300
SAN DIEGO, CA 92130
X



Signatures
/s/ Robert O. Hopkins, Power of Attorney for Roshawn A. Blunt2/13/2020
**Signature of Reporting PersonDate

Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more Adamis Pharmaceuticals Charts.
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more Adamis Pharmaceuticals Charts.